{
    "id": 26672,
    "fullName": "TFG - MET",
    "impact": "fusion",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "TFG-MET results from the fusion of TFG and MET, which leads to increased phosphorylation of Erk, Stat1, and Stat3, and is transforming in cultured cells (PMID: 28512244). TFG-MET has been identified in thyroid carcinoma (PMID: 28512244) and infantile spindle cell sarcoma (PMID: 28510278).",
            "references": [
                {
                    "id": 12299,
                    "pubMedId": 28510278,
                    "title": "TFG-MET fusion in an infantile spindle cell sarcoma with neural features.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28510278"
                },
                {
                    "id": 9257,
                    "pubMedId": 28512244,
                    "title": "Engineering and Functional Characterization of Fusion Genes Identifies Novel Oncogenic Drivers of Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28512244"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 10342,
        "geneSymbol": "TFG",
        "terms": [
            "TFG",
            "HMSNP",
            "SPG57",
            "TF6",
            "TRKT3"
        ]
    },
    "variant": "TFG - MET",
    "createDate": "07/03/2017",
    "updateDate": "10/18/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 4233,
                "geneSymbol": "MET",
                "terms": [
                    "MET",
                    "AUTS9",
                    "c-Met",
                    "DFNB97",
                    "HGFR",
                    "RCCP2"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 11363,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing TFG-MET demonstrated sensitivity to Xalkori (crizotinib) in culture (PMID: 28512244).",
            "molecularProfile": {
                "id": 27967,
                "profileName": "TFG - MET"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9257,
                    "pubMedId": 28512244,
                    "title": "Engineering and Functional Characterization of Fusion Genes Identifies Novel Oncogenic Drivers of Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28512244"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 27967,
            "profileName": "TFG - MET",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}